EGFR and non-small cell lung carcinoma: This retrospective study followed patients treated in the real-world setting of US oncology practices for advanced nonsquamous NSCLC with sensitizing EGFR mutations (ex19del/L858R) and who initiated platinum-containing chemotherapy from 2011 to mid-2020 after having received one or two lines of EGFR TKI therapy, with follow-up to mid-2022.